Table 1.
Baseline disease characteristics
| Placebo | Guselkumab | Adalimumab | Total | |
|---|---|---|---|---|
| Patients randomized at week 0, N | 422 | 825 | 582 | 1829 |
| Psoriasis disease duration, years | ||||
| N | 422 | 825 | 582 | 1829 |
| Mean ± SD | 17.8 ± 12.1 | 17.9 ± 12.1 | 17.3 ± 11.4 | 17.7 ± 11.9 |
| Median | 15.0 | 16.0 | 15.0 | 15.0 |
| BSA, % involvement | ||||
| N | 422 | 825 | 582 | 1829 |
| Mean ± SD | 27.1 ± 16.3 | 28.4 ± 16.7 | 28.8 ± 16.7 | 28.2 ± 16.6 |
| Median | 21.0 | 23.0 | 24.0 | 23.0 |
| DLQI score (0–30) | ||||
| N | 418 | 817 | 575 | 1810 |
| Mean ± SD | 14.3 ± 7.2 | 14.4 ± 7.2 | 14.6 ± 7.1 | 14.5 ± 7.2 |
| Median | 14.0 | 14.0 | 14.0 | 14.0 |
| PASI score (0–72) | ||||
| N | 422 | 825 | 582 | 1829 |
| Mean ± SD | 21.1 ± 8.3 | 22.0 ± 9.1 | 22.1 ± 9.0 | 21.8 ± 8.9 |
| Median | 18.3 | 19.0 | 19.5 | 19.0 |
| IGA score (0–4), N (%) | ||||
| N | 422 | 825 | 582 | 1829 |
| Moderate (3) | 322 (76.3) | 632 (76.6) | 436 (74.9) | 1390 (76.0) |
| Severe (4) | 100 (23.7) | 192 (23.3) | 143 (24.6) | 435 (23.8) |
| PSSD symptom score (0–100) | ||||
| N | 327 | 660 | 475 | 1462 |
| Mean ± SD | 54.5 ± 24.1 | 54.2 ± 25.6 | 53.8 ± 25.9 | 54.2 ± 25.3 |
| Median | 54.0 | 54.0 | 56.0 | 54.0 |
| PSSD sign score (0–100) | ||||
| N | 327 | 660 | 475 | 1462 |
| Mean ± SD | 58.1 ± 20.5 | 56.5 ± 22.1 | 57.8 ± 21.6 | 57.3 ± 21.6 |
| Median | 58.0 | 57.5 | 58.0 | 58.0 |
BSA body surface area, DLQI Dermatology Life Quality Index, IGA Investigator’s Global Assessment, PASI Psoriasis Area and Severity Index, PSSD Patient Symptoms and Signs Diary, SD standard deviation